Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Grown tumor organoids could guide bladder cancer treatment

NCT ID NCT05024734

Disease control Sponsor: Roland Seiler-Blarer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial tests whether lab-grown miniature tumors, called organoids, can help choose the best chemotherapy for people with intermediate-risk bladder cancer. Tumor samples are taken during surgery and grown in the lab. After testing several drugs on the organoids, the most effective one is given directly into the bladder. The goal is to see if this personalized approach is feasible and may reduce the chance of cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Epirubicin, Mitomycin, Gemcitabine, Docetaxel
What this could lead to
If successful, this approach could personalize bladder cancer treatment, reducing recurrence by selecting the most effective drug for each patient.
What could go wrong
This is a small, early-phase trial focused on feasibility, not yet on long-term outcomes. Organoid growth may fail, and drug selection may not improve recurrence rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

31 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Signed Informed Consent Form * ECOG performance status of 0 or 1 * Histologically confirmed intermediate risk non muscle-invasive urothelial carcinoma of the bladder (pTa low grade) Patients * Representative fresh tumor specimen for PDO generation and drug screen Exclusion Criteria: * Known previous high grade and/or high risk non muscle-invasive bladder cancer * Previous Intravesical biological/immuno (BCG) therapy * Pregnancy or nursing * Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol * Severe infection within 4 weeks prior to cycle 1, day 1 * Contraindication for frequent catheterization * Voiding dysfunction * Pregnancy or nursing * Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 6 months after the last treatment. * Male subject who is unwilling to use acceptable method of effective contraception during IP treatment and through 6 months after the last dose of IP.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer Non-muscle invasive

Contacts and locations

Locations

  • Spitalzentrum Biel/Bienne

    Biel, 2501, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.